- Home
- AACG vs NNVC Comparison
AACG vs NNVC Comparison
Compare AACG & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- NNVC
- Stock Information
- Founded
- AACG 1999
- NNVC 2005
- Country
- AACG China
- NNVC United States
- Employees
- AACG N/A
- NNVC N/A
- Industry
- AACG Other Consumer Services
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- AACG Real Estate
- NNVC Health Care
- Exchange
- AACG Nasdaq
- NNVC Nasdaq
- Market Cap
- AACG 28.2M
- NNVC 24.4M
- IPO Year
- AACG N/A
- NNVC N/A
- Fundamental
- Price
- AACG $0.77
- NNVC $1.23
- Analyst Decision
- AACG
- NNVC
- Analyst Count
- AACG 0
- NNVC 0
- Target Price
- AACG N/A
- NNVC N/A
- AVG Volume (30 Days)
- AACG 11.4K
- NNVC 213.1K
- Earning Date
- AACG 08-06-2025
- NNVC 05-15-2025
- Dividend Yield
- AACG N/A
- NNVC N/A
- EPS Growth
- AACG N/A
- NNVC N/A
- EPS
- AACG N/A
- NNVC N/A
- Revenue
- AACG $37,997,003.00
- NNVC N/A
- Revenue This Year
- AACG N/A
- NNVC N/A
- Revenue Next Year
- AACG N/A
- NNVC N/A
- P/E Ratio
- AACG N/A
- NNVC N/A
- Revenue Growth
- AACG 21.24
- NNVC N/A
- 52 Week Low
- AACG $0.50
- NNVC $0.94
- 52 Week High
- AACG $1.10
- NNVC $2.55
- Technical
- Relative Strength Index (RSI)
- AACG 35.81
- NNVC 36.88
- Support Level
- AACG $0.75
- NNVC $1.36
- Resistance Level
- AACG $0.86
- NNVC $1.46
- Average True Range (ATR)
- AACG 0.04
- NNVC 0.09
- MACD
- AACG -0.01
- NNVC -0.03
- Stochastic Oscillator
- AACG 11.71
- NNVC 19.05
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments are Overseas art study services, Other educational services and K-12 education assessment and other services. Majority of its revenue comes from Overseas art study services.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.